Straits Times Index
3,305.82 +2.63 (+0.08%) Nikkei
38,786.54 +550.47 (+1.44%) Hang Seng
18,420.38 -157.92 (-0.85%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,333.43 -621.91 (-0.97%) CMC Crypto 200
1,360.17 +47.55 (+3.62%)
VRTX May 2024 220.000 call
| Previous close | 173.80 |
| Open | 173.80 |
| Bid | 176.20 |
| Ask | 186.00 |
| Strike | 220.00 |
| Expiry date | 2024-05-03 |
| Day's range | 173.80 - 173.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
- Reuters
UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
GuruFocus.comVertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
ZacksVertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
